Navigation Links
Cell Therapeutics, Inc. (CTI) Cuts Net Operating Expenses 35% and Expands Commercial Team to Support Zevalin(R) Sales and Applications Seeking Two Product Approvals in 2009
Date:1/30/2008

and pixantrone. This year we will continue to prepare for submission of a marketing authorization application for XYOTAX and the evaluation of pivotal trial data for pixantrone. Our goal is to ensure that we succeed with Zevalin and are prepared for the future market introductions of XYOTAX and pixantrone."

"On a personal note, while we are adding staff in some areas, it is with great disappointment that we must reduce headcount elsewhere in order to meet these goals," Bianco added.

CTI has begun building a new sales and marketing department to support Zevalin sales. The company will be adding more than 13 positions for Zevalin and other potential drug sales. The Company has also increased staffing in regulatory and manufacturing in preparation for filing for approval of XYOTAX in Europe in March.

About ZEVALIN(R)

Zevalin (Ibritumomab Tiuxetan) is a form of cancer therapy called radioimmunotherapy and is indicated for the treatment of patients with relapsed or refractory low-grade or follicular B-cell NHL, including patients with Rituximab-refractory NHL. It was approved by the FDA in February of 2002 as the first radioimmunotherapeutic agent for the treatment of NHL.

Deaths associated with an infusion reaction symptom complex have occurred within 24 hours of rituximab infusions. Yttrium-90 Zevalin administration results in severe and prolonged cytopenias in most patients. Severe cutaneous and mucocutaneous reactions have been reported. The most serious adverse reactions of the Zevalin therapeutic regimen were primarily hematologic, including neutropenia, thrombocytopenia, and anemia. Infusion-related toxicities were associated with pre-administration of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health car
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Reckitt Benckiser Completes Acquisition of Adams Respiratory Therapeutics, Inc.
2. Cell Therapeutics, Inc. (CTI) Completes Acquisition of Lymphoma Drug Zevalin(R) From Biogen Idec for Sales and Marketing in the United States
3. Cell Therapeutics, Inc. Announces $6.5 Million Offering
4. Cell Therapeutics, Inc. (CTI) Plans to Submit Supplemental Biologics License Application (sBLA) for ZEVALIN(R) Consolidation of First Remission in Advanced Stage Follicular Lymphoma in 2008
5. Clinical Trial Investigators Update Wall Street on Progress and Prospects of Cell Therapeutics, Inc.s Drug Pipeline
6. InteKrin Therapeutics, Inc. Appoints Former Amgen Clinical Development Executive Chief Medical Officer
7. Cell Therapeutics, Inc. (CTI) Appoints Jim Fong as Vice President, Commercial Operations
8. Cell Therapeutics, Inc. (CTI) Reports Recent Accomplishments and Third Quarter 2007 Financial Results
9. Cell Therapeutics, Inc. (CTI) to Report Third Quarter Financial Results on November 8
10. Cell Therapeutics, Inc. (CTI) CIBC and Rodman & Renshaw Healthcare Conference Presentations to be Webcast
11. Sontra Medical Corporation Changes Name to Echo Therapeutics, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... (Nov. 8, 2011) - Patients who are not ... lesions could be treated with carotid artery stenting, according ... at The University of Texas Health Science Center at ... by lead investigator Colin M. Barker, M.D., at the ...
... , TUESDAY, Nov. 8 (HealthDay News) -- The reversal ... of receiving a new organ from a deceased donor, U.S. ... Sharing (UNOS) gave priority to potential recipients who had a ... an antigen involved in the body,s immune response to foreign ...
... on Dec. 1, University of Cincinnati research is shedding light ... AIDS and HIV infections. An Ohio survey conducted by Matthew ... AIDS remains a public health concern. Asare surveyed just ... AIDS/HIV and sex all subjects that are considered taboo ...
... Smoking bans in public places have had a spillover effect ... new study. U.S. researchers analyzed data from a nationally ... who lived in counties with total smoking bans in workplaces, ... bans at home. Homes with children were most likely ...
... TUESDAY, Nov. 8 (HealthDay News) -- New research finds older ... than younger women, suggesting that older patients may not be ... over the past three decades. Researchers analyzed U.S. government ... death rates were stable throughout the 1980s for women aged ...
... it sounds like good news: The body,s own immune ... not necessarily for the benefit of the patient. "We ... Professor Dr. Viktor Umansky, immunologist at DKFZ and University ... the immune system specifically attack tumor cells. On the ...
Cached Medicine News:Health News:Racial Disparities Still Exist for Kidney Recipients, Study Finds 2Health News:Survey finds that AIDS remains an unspeakable subject for African immigrants 2Health News:Public Smoking Bans May Spill Over to Households 2Health News:Advances in Breast Cancer Care May Not Be Reaching Older Women 2Health News:Using Viagra to combat malignant melanoma 2
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Cryo System is the first in portability and performance. ... surgeons who need a flexible, portable system with the ... CTU attaches easily to an "E" size tank and ... cryo to where it is needed.,The CTU Travel Case ...
... easy-to-use, workflow-based system designed to save you time ... the SleepWorks software and either the Connex or ... can be used for a complete range of ... EEG recording - and have superior signal quality ...
... made up of three integral components including ... Merci Balloon Guide Catheter. The system employs ... the clot has been identified using angiography, ... through a small incision in the femoral ...
... level of care you can provide to ... care program, including innovative products, standardization and ... Davol® pulsed lavage systems deliver the performance ... tissue, bacteria, and foreign material. Each provides ...
Medicine Products: